Personal Research Database Bibliometric

Title: Theranostics

ISO Abbreviated Title: Theranostics

JCR Abbreviated Title: Theranostics

ISSN:

Journal Country/Territory:

Language:

Publisher:

Publisher Address:

Subject Categories:

: Impact Factor

? Ho, D.N., Choi, K.Y. and Lee, S.J. (2013), Bibliometric analysis of Theranostics: Two years in the making. Theranostics, 3 (7), 527-531.

Full Text: 2013\Theranostics3, 527.pdf

Abstract: With the newly released impact factor from Thomson Reuters, we look at the first two years of the journal Theranostics under the scope of a new bibliometric designed for the analysis of emerging specialties and also for journals with a multidisciplinary approach. With this method, we are able to look at characteristics of an interdisciplinary field or a single journal subject area, and also, the bibliographic trends of their authors. We use this tool to examine authors from the journal Theranostics and compare them to similar authors in the field of theranostics, or theranosticians. Our document and co-citation analysis examines the growth and overlap of established knowledge networks with the incorporation of fields, topics, and disciplines; the quantification can also reflect the intellectual activity in combining leading edge developments in solidly grounded specialties. The quantification of junior authorship aims to gauge the promotion of fresh ideas and scientific development in the community, while productivity of overall authors is measured by citation analysis.

Keywords: Activity, Analysis, Approach, Authors, Authorship, Bibliographic, Bibliometric, Bibliometric Analysis, Characteristics, Citation, Citation Analysis, Co-Citation, Co-Citation Analysis, Cocitation, Combining, Community, Development, Disciplines, Field, First, Growth, Impact, Impact Factor, Interdisciplinary, Journal, Journals, Knowledge, Multidisciplinary, Networks, Productivity, Promotion, Quantification, Scope, Thomson Reuters, Thomson-Reuters, Trends

Title: Therapeutic Drug Monitoring

ISO Abbreviated Title:

JCR Abbreviated Title:

ISSN:

Journal Country/Territory:

Language:

Publisher:

Publisher Address:

Subject Categories:

: Impact Factor

? Boscolo-Berto, R., Favretto, D., Cecchetto, G., Vincenti, M., Kronstrand, R., Ferrara, S.D. and Viel, G. (2014), Sensitivity and specificity of EtG in hair as a marker of chronic excessive drinking: Pooled analysis of raw data and meta-analysis of diagnostic accuracy studies. Therapeutic Drug Monitoring, 36 (5), 560-575.

Full Text: 2014\The Dru Mon36, 560.pdf

Abstract: Background: To assess the debated diagnostic performance of ethyl glucuronide in the 3-cm proximal scalp hair fraction (HEtG) as a marker of chronic excessive drinking. Methods: In July 2012/May 2013, after a systematic search through the MEDLINE, OVID/EMBASE, WEB OF SCIENCE, and SCOPUS databases, 8 studies were included in the pooled analysis that report raw single data on HEtG concentration and self-reported daily alcohol intake (SDAI). A receiver operating characteristic curve analysis and a Spearman rank-order correlation test were used. A meta-analysis was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Cochrane recommendations, comprising quality and bias assessments. Results: The pooled analysis showed that 30 pg/mg could be a useful cutoff value for HEtG to detect an SDAI >60 g/d and demonstrated a parabolic direct correlation between HEtG and SDAI data [rho 0.79; 95% confidence interval (CI), 0.69-0.87; P < 0.001]. The meta-analysis found an overall HEtG sensitivity of 0.96 (95% CI, 0.72-1.00) and a specificity of 0.99 (95% CI, 0.92-1.00); a nomogram to predict the posttest probability of exhibiting the targeted condition in the general population was built. Significant variability among the included studies was detected, which was mainly explained by true heterogeneity in the presence of publication bias. Conclusions: With the available data, we conclude that HEtG is a promising marker for identifying chronic excessive drinking. Nonetheless, larger and well-designed population studies are required to draw any definitive conclusions on the significance and appropriateness of its application in the forensic setting.

Keywords: Acid Ethyl-Esters, Alcohol, Alcohol Abuse, Alcohol Intake, Alcohol-Abuse, Analysis, Application, Assessments, Bias, Chronic, Concentration, Confidence, Consumption, Correlation, Data, Databases, Diagnostic, ETG, Ethyl Glucuronide, Forensic, General, General Population, Glucuronide Levels, Hair, Harmful Drinking, Head Hair, Heterogeneity, Interval, Marker, Mass-Spectrometry, Medline, Meta Analysis, Meta-Analysis, Metaanalysis, Methods, Nomogram, Of-Science, Of-The-Art, P, Performance, Phosphatidylethanol, Pooled Analysis, Population, Publication, Publication Bias, Quality, Receiver Operating Characteristic Curve, Recommendations, Results, Scalp, Science, Scopus, Sensitivity, Significance, Specificity, Systematic, Systematic Reviews, Value, Variability, Web, Web-Of-Science

Title: Therapeutics and Clinical Risk Management

ISO Abbreviated Title:

JCR Abbreviated Title:

ISSN:

Journal Country/Territory:

Language:

Publisher:

Publisher Address:

Subject Categories:

: Impact Factor

? Wang, Z.Y., Chen, M., Zhu, L.L., Yu, L.S., Zeng, S., Xiang, M.X. and Zhou, Q. (2015), Pharmacokinetic drug interactions with clopidogrel: Updated review and risk management in combination therapy. Therapeutics and Clinical Risk Management, 11, 449-467.

Full Text: 2015\The Cli Ris Man11, 449.pdf

Abstract: Background: Coprescribing of clopidogrel and other drugs is common. Available reviews have addressed the drug-drug interactions (DDIs) when clopidogrel is as an object drug, or focused on combination use of clopidogrel and a special class of drugs. Clinicians may still be ignorant of those DDIs when clopidogrel is a precipitant drug, the factors determining the degree of DDIs, and corresponding risk management. Methods: A literature search was performed using PubMed, MEDLINE, Web of Science, and the Cochrane Library to analyze the pharmacokinetic DDIs of clopidogrel and new P2Y12 receptor inhibitors. Results: Clopidogrel affects the pharmacokinetics of cerivastatin, repaglinide, ferulic acid, sibutramine, efavirenz, and omeprazole. Low efficacy of clopidogrel is anticipated in the presence of omeprazole, esomeprazole, morphine, grapefruit juice, scutellarin, fluoxetine, azole antifungals, calcium channel blockers, sulfonylureas, and ritonavir. Augmented antiplatelet effects are anticipated when clopidogrel is coprescribed with aspirin, curcumin, cyclosporin, St John’s wort, rifampicin, and angiotensin-converting enzyme inhibitors. The factors determining the degree of DDIs with clopidogrel include genetic status (eg, cytochrome P540 [CYP] 2B6*6, CYP2C19 polymorphism, CYP3A5*3, CYP3A4*1G, and CYP1A2-163C>A), species differences, and dose strength. The DDI risk does not exhibit a class effect, eg, the effects of clopidogrel on cerivastatin versus other statins, the effects of proton pump inhibitors on clopidogrel (omeprazole, esomeprazole versus pantoprazole, rabeprazole), the effects of rifampicin on clopidogrel versus ticagrelor and prasugrel, and the effects of calcium channel blockers on clopidogrel (amlodipine versus P-glycoprotein-inhibiting calcium channel blockers). The mechanism of the DDIs with clopidogrel involves modulating CYP enzymes (eg, CYP2B6, CYP2C8, CYP2C19, and CYP3A4), paraoxonase-1, hepatic carboxylesterase 1, P-glycoprotein, and organic anion transporter family member 1B1. Conclusion: Effective and safe clopidogrel combination therapy can be achieved by increasing the awareness of potential changes in efficacy and toxicity, rationally selecting alternatives, tailoring drug therapy based on genotype, checking the appropriateness of physician orders, and performing therapeutic monitoring.

Keywords: Alternatives, Amlodipine, Aspirin, Awareness, Calcium, Calcium Channel Blockers, Calcium-Channel Blockers, Changes, Clopidogrel, Combination Therapy, Coronary Stent Implantation, Cyp2c19, Cytochrome, Drug, Drug Interactions, Drug Metabolism, Drug Therapy, Drug Transporter, Drug-Drug Interactions, Drugs, Effects, Efficacy, Enzymes, Esomeprazole, Factors, Family, Fluoxetine, Genetic, Genotype, Healthy Male-Subjects, Human Cytochrome-P450, In-Vitro, Inhibitors, Literature, Literature Search, Management, Mechanism, Medline, Methods, Monitoring, Morphine, Myocardial-Infarction, Organic, P-Glycoprotein, P2y(12) Receptor Inhibitors, P2y(12) Receptor Inhibitors, Paraoxonase 1, Pharmacogenetics, Pharmacokinetic, Pharmacokinetics, Physician, Polymorphism, Polypharmacy, Potential, Proton-Pump Inhibitors, Pubmed, Pump, Results, Review, Reviews, Rifampicin, Risk, Risk Management, Science, Species, Statins, Steady-State Pharmacokinetics, Strength, Therapeutic, Therapeutic Monitoring, Therapy, Toxicity, Transporter, Web, Web Of Science